CYTIVA STRENGTHENS CELL LINE DEVELOPMENT WITH CEVEC ACQUISITION

• Viral vector manufacturing and cell line development are keystone technologies in the making of gene therapies
• 46 scientific experts based in Cologne, Germany, join the Cytiva team in the genomic medicine space
• Cytiva customers will have immediate access to technologies that solve some of the greatest challenges in bringing gene therapies to patients

October 6, 2022